In human thyroid cancer cells, treatment with BRAF V600E and MEK inhibitors increased H3K9/14 and H4K16 acetylation mainly at regions P1 (−692/−370) and P2 (−1147/−762) of the human NIS promoter, suggesting that BRAF V600E/MEK normally exerts a negative effect on histone acetylation at regions P1 and P2 of the NIS promoter in human thyroid cancer cells. Here, SLC5A5 is linked to thyroid gland carcinoma.